Home | Publications | In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

Published on: 1 January, 2021

Malla SB, Fisher DJ, Domingo E, Blake A, Hassanieh S, Redmond KL, et al. In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. Clin Cancer Res. 2021 Jan 1;27(1):288-300

Link to Publication

Related Themes

In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

Published on: 1 January, 2021

Related Themes

Multidisciplinary Pathology

Oncology

Related Team Members

Dr Susan Richman

Multidisciplinary Pathology Deputy Lead

Professor Philip Quirke

Multidisciplinary Pathology Theme Lead